Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The FDA/SAHPRA does not allow product claims on dietary supplement products
Presented for research literature review only Jian-bo L et al
Risk Matters When Considering Alternatives For patients at moderate to high risk of disease progression, standard immunosuppressive treatments remain essential
Second Indication: glycemic control in adults with type 2 diabetes: Monotherapy For adults with type 2 diabetes who have inadequate glycemic control despite diet and exercise interventions
US$ 25.42
US$ 28.15
US$ 28.14
US$ 28.63
US$ 25.06
US$ 24.61
US$ 22.18
US$ 28.38
US$ 25.43
US$ 21.27
US$ 23.69
US$ 21.82
US$ 20.25
